FDA Seeks Input on Biosimilar Fee Hike for 2028
Published Date: 11/24/2025
Notice
Summary
The FDA is gearing up to renew the Biosimilar User Fee Act, which helps fund the review of biosimilar drugs from 2028 to 2032. They’re hosting a public meeting on December 3, 2025, and want your thoughts by January 2, 2026. This affects drug makers and patients by keeping biosimilar reviews speedy and efficient, with fees supporting the process.
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Keeps Biosimilar Reviews Funded
The FDA is seeking reauthorization of the Biosimilar User Fee Act for fiscal years 2028 through 2032. The law lets FDA collect user fees so it can hire staff and improve systems to keep biosimilar reviews moving and make biosimilar therapies available to patients sooner; the current authority expires in September 2027.
Drug Makers Will Pay User Fees
If reauthorized for FYs 2028 through 2032, BsUFA authorizes FDA to assess and collect fees from drug companies that submit marketing applications for biosimilar biological products. The notice notes the current legislative authority expires in September 2027 and invites input on fee structures and amounts by January 2, 2026.
Expedited Reviews and Interchangeability Work
The current BsUFA (BsUFA III) includes new supplement categories, timelines, and performance goals to expedite review of supplemental biosimilar applications and establishes a regulatory science pilot to advance development of interchangeable biosimilars. Those procedures aim to improve the efficiency of development and review for biosimilar and interchangeable products.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-12577 — Agency Information Collection Activities; Proposed Collection; Comment Request; Potential Tobacco Product Violations Reporting Form
The FDA wants your thoughts on a new form to report possible tobacco product rule-breakers. This affects anyone who might spot tobacco violations and helps the FDA keep products safe. You’ve got until August 24, 2026, to share your comments—no cost to you, just your voice!
2026-12579 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Certification of Identity, Form FDA 3975
The FDA is asking for approval to keep using Form FDA 3975, which helps confirm who you are when you ask for your own records under the Freedom of Information Act or Privacy Act. If you want your personal info from the FDA but didn’t prove your identity well enough, this form steps in. Comments on this plan are open until July 23, 2026, and there’s no new cost for you—just a smoother way to get your info!
2026-12367 — Epizyme, Inc.; Withdrawal of Approval of New Drug Application for TAZVERIK (Tazemetostat) Tablet, 200 Milligrams
Epizyme, Inc. has asked the FDA to withdraw approval for their cancer drug TAZVERIK (200 mg tablets), effective June 22, 2026. This means TAZVERIK will no longer be officially approved for treating certain sarcomas and lymphomas, affecting patients and healthcare providers relying on it. The change might impact treatment options and insurance coverage, so folks should check with their doctors about next steps.
2026-12444 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Light-Projecting Measuring Device
The FDA is officially putting the endoscopic light-projecting measuring device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while speeding up patient access to cool new tech. The new rules took effect June 22, 2026, and could save time and money for makers and users alike.
2026-12445 — Medical Devices; Gastroenterology-Urology Devices; Classification of the Endoscopic Traction Device
The FDA is officially putting the endoscopic traction device into Class II, meaning it now has special safety rules but fewer hurdles than the strictest category. This change helps make sure the device is safe and effective while making it easier for patients to get access to this cool medical tool. The new rules took effect on June 22, 2026, and could speed up innovation without extra costs for makers.
2026-12443 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple In Vitro Diagnostic Device for the Detection of Secreted Proteins From Bacillus Species (spp.) in Human Clinical Samples
The FDA is officially putting a simple test that spots proteins from Bacillus bacteria in human samples into a safer, easier-to-manage category called Class II. This change helps make sure the test is safe and works well while speeding up patient access to cool new medical tools. The new rules kicked in on June 22, 2026, but have been in effect since February 3, 2023, making life simpler for device makers and patients alike.
Previous / Next Documents
Previous: 2025-20653 — Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Request for Comment; Occupant Anthropometry and Seating
The National Highway Traffic Safety Administration (NHTSA) is asking for approval to collect new info about how people’s body sizes and seating affect vehicle safety. This affects anyone involved in vehicle design and safety research, aiming to make cars safer and more comfortable. Comments on this plan are open until December 24, 2025, with no big costs expected for the public.
Next: 2025-20655 — Pipeline Safety: Request for Special Permit; Southern Natural Gas Company, LLC (SNG)
Southern Natural Gas Company (SNG) asked for a special permit to skip some pipeline safety rules, but only if they follow new safety conditions. The government wants your thoughts on this by December 24, 2025, before deciding. This affects SNG’s operations and could change how they manage pipeline safety without extra costs right now.